Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Guardant Health, Inc. - Common Stock (NQ: GH )

42.89 +2.25 (+5.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Debt Exchange Transactions
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Guardant Health, Inc.
Via Business Wire
Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
From Guardant Health, Inc.
Via Business Wire
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
From Guardant Health, Inc.
Via Business Wire
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
From COTA Inc.
Via Business Wire
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Named to TIME’s List of the Best Inventions of 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
From Guardant Health, Inc.
Via Business Wire
Roberto A. Mignone Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
From Guardant Health, Inc.
Via Business Wire
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.